- Else Nutrition (BABY) has concluded a second successful preclinical study of its plant-based infant formula
- The successful study marks a crucial step forward in bringing the company’s 0-12 month infant formula to market by validating the product’s safety and benefits
- Else Nutrition GH Ltd. is an Israel-based food and nutrition company
- Else Nutrition Holdings Inc. (BABY) opened trading at C$1.40
Else Nutrition (BABY) has concluded a second successful preclinical study of its plant-based infant formula.
The completed preclinical study marks a crucial step forward in bringing the company’s 0-12 month infant formula to market by validating the product’s safety and benefits.
The study’s results confirmed proper protein efficiency in a preclinical model, demonstrating the protein bioavailability of Else’s infant formula.
Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition commented on the news.
“This is a big step forward for the company. Since inception, our vision has been to fill the major market gap for an alternative to dairy and bring a whole-food, plant-based, soy-free infant formula to millions of families worldwide. These results mark further validation of our formulation, as we continue to push ahead in seeking FDA approval.”
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults.
Else Nutrition Holdings Inc. (BABY) opened trading at C$1.40.
